echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JCEM: Hyperglucagonemia in childhood obesity is associated with cardiometabolic risk factors but not hyperglycemia

    JCEM: Hyperglucagonemia in childhood obesity is associated with cardiometabolic risk factors but not hyperglycemia

    • Last Update: 2022-04-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Background: Glucagon opposes the hypoglycemic effect of insulin and stimulates hepatic glucose production


    Glucagon also mediates several metabolic effects not related to glucose, including regulation of amino acid metabolism (urea production); stimulation of insulin secretion; breakdown of fatty acids in the liver and inhibition of lipogenesis; potential reduction in food intake; increased energy expenditure ; and may modulate heart rate and contractility, although the latter effect may not be physiological


    METHODS: A cross-sectional Holbaek study of overweight/obese children and adolescents aged 6 to 19 years was performed in the obese outpatient group (n=2154) and the normal weight group (n=1858)


    Results: The level of glucagon in the obese clinical group was significantly higher than that in the human group (P<0.


    Figure 1


    Figure 1


    Figure 2.


    Figure 2.


    Figure 3: Estimated ORs (95% CI) of fasting plasma glucagon as an indicator of cardiometabolic risk profile in the pooled model, adjusted for age, sex, and body mass index SDS


    Figure 3: Estimated ORs (95% CI) of fasting plasma glucagon as an indicator of cardiometabolic risk profile in the pooled model, adjusted for age, sex, and body mass index SDS


    Fasting glucagon concentrations were elevated in overweight/obese children and adolescents compared with normal-weight peers, which corresponded to worsening cardiometabolic risk outcomes other than hyperglycemia


    Hyperglucagonemia in pediatric adiposity associates with cardiometabolic risk factors but not

    hyperglycemia
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.